3 - Kenvue Inc. (0001944048) (Issuer)

4 - Kenvue Inc. (0001944048) (Issuer)

4 - Kenvue Inc. (0001944048) (Issuer)

4 - Kenvue Inc. (0001944048) (Issuer)

4 - Kenvue Inc. (0001944048) (Issuer)

4 - Kenvue Inc. (0001944048) (Issuer)

4 - Kenvue Inc. (0001944048) (Issuer)

4 - Kenvue Inc. (0001944048) (Issuer)

3 - Kenvue Inc. (0001944048) (Issuer)

3 - Kenvue Inc. (0001944048) (Issuer)

Canaccord Genuity downgraded Kenvue from Buy to Hold and set a new price target of $15.00

Rothschild & Co Redburn upgraded Kenvue from Neutral to Buy and set a new price target of $22.00

Redburn Atlantic initiated coverage of Kenvue with a rating of Neutral and set a new price target of $23.50

Evercore ISI initiated coverage of Kenvue with a rating of In-line and set a new price target of $25.00

Piper Sandler upgraded Kenvue from Neutral to Overweight and set a new price target of $26.00 from $21.00 previously

Deutsche Bank downgraded Kenvue from Buy to Hold and set a new price target of $24.00 from $25.00 previously

Jefferies initiated coverage of Kenvue with a rating of Buy and set a new price target of $27.00

RBC Capital Mkts downgraded Kenvue from Outperform to Sector Perform and set a new price target of $24.00

Citigroup resumed coverage of Kenvue with a rating of Neutral and set a new price target of $21.00

Bernstein initiated coverage of Kenvue with a rating of Underperform and set a new price target of $18.00

425 - Kenvue Inc. (0001944048) (Subject)

SCHEDULE 13G/A - Kenvue Inc. (0001944048) (Subject)

425 - Kenvue Inc. (0001944048) (Subject)

425 - Kenvue Inc. (0001944048) (Subject)

425 - Kenvue Inc. (0001944048) (Subject)

425 - Kenvue Inc. (0001944048) (Subject)

425 - Kenvue Inc. (0001944048) (Subject)

425 - Kenvue Inc. (0001944048) (Subject)

425 - Kenvue Inc. (0001944048) (Subject)

425 - Kenvue Inc. (0001944048) (Subject)

SC 13G/A - Kenvue Inc. (0001944048) (Subject)

SC 13G/A - Kenvue Inc. (0001944048) (Subject)

SC 13G/A - Kenvue Inc. (0001944048) (Subject)

SC 13G/A - Kenvue Inc. (0001944048) (Subject)

SC 13G/A - Kenvue Inc. (0001944048) (Subject)

SC 13G/A - Kenvue Inc. (0001944048) (Subject)

Combines Highly Complementary and Strategically Aligned Consumer Offerings, Including 10 Iconic Billion-Dollar Brands, That Will Provide Preferred Solutions Through Every Stage of Life Applies Kimberly-Clark's Proven Commercial Execution Playbook to Create a Best-in-Class Consumer-Driven Company Accelerates Kenvue's Premier Consumer Health Portfolio and Strong Science-Backed Innovation, Supported by Talented Kenvue Team Enhances Investment in Marketing, Innovation and R&D Capabilities to Strengthen Combined Company's Unique Advantages Total Anticipated Run-Rate Synergies of $2.1 Billion; Expected to Be Accretive to Kimberly-Clark's Adjusted EPS By Year 2 Delivers Immediate Upfront Value to K

Net Sales (3.5)%; Organic Sales1 (4.4)% Diluted EPS was $0.21; Adjusted Diluted EPS1 was $0.28 Affirms Outlook for FY'25 Kirk Perry Named Permanent Chief Executive Officer and Company Announced Additional Key Leadership Appointments Kenvue Inc. (NYSE:KVUE) today announced financial results for the third quarter ended September 28, 2025. "Throughout the third quarter, our team remained focused on our four operating priorities to drive improved performance," said Kirk Perry, Chief Executive Officer. "Third quarter results keep us on track to deliver our full year guidance and we are confident in the decisive actions we are taking to accelerate Kenvue's performance and unlock th

Kenvue Inc. (NYSE:KVUE) today announced that its Board of Directors declared a quarterly dividend of $0.2075 per share on its common stock. The quarterly dividend is payable on November 26, 2025, to shareholders of record as of the close of business on November 12, 2025. About Kenvue Kenvue Inc. is the world's largest pure-play consumer health company by revenue. Built on more than a century of heritage, our iconic brands, including Aveeno®, BAND-AID® Brand, Johnson's®, Listerine®, Neutrogena® and Tylenol®, are science-backed and recommended by healthcare professionals around the world. At Kenvue, we realize the extraordinary power of everyday care. Our teams work every day to put that po

Kenvue Inc. (NYSE:KVUE) will announce its third quarter 2025 financial results before the market opens on November 6, 2025. The company will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss its financial results. The conference call can be accessed by dialing 877-407-8835 from the U.S. or +1 201-689-8779 from international locations. A live webcast of the conference call can also be accessed at investors.kenvue.com, with a replay made available after the live event. About Kenvue Kenvue Inc. is the world's largest pure-play consumer health company by revenue. Built on more than a century of heritage, our iconic brands, including Aveeno®, BAND-AID® Brand, Johnson'

Frontier AI company Albert Invent today announced a strategic partnership with Kenvue Inc. (NYSE:KVUE), maker of consumer health products like Zyrtec®, Neutrogena®, and Listerine®, to accelerate end-to-end R&D efforts across the company's global portfolio of brands. The partnership enables Kenvue to streamline, digitalize, and accelerate the end-to-end product lifecycle by leveraging Albert Invent's foundational AI models. The companies began working together starting in Q1 2025 as part of a multi-year partnership set to drive value for scientists by streamlining hundreds of R&D processes and methodologies across the globe. The focus of the partnership is to augment and accelerate the wor

Net Sales (4.0)%; Organic Sales1 (4.2)% Diluted EPS was $0.22; Adjusted Diluted EPS1 was $0.29 Continues to Advance Ongoing Review of Strategic Alternatives, While Taking Actions to Accelerate Profitable Growth Under the New Executive Team Revises Outlook for FY'25 Kenvue Inc. (NYSE:KVUE) today announced financial results for the second quarter ended June 29, 2025. "Kenvue has a strong portfolio of world-class, category-defining brands. We are actively focused on improving execution and performance, while advancing the comprehensive strategic alternatives review, to deliver our inherent value," said Kirk Perry, Interim Chief Executive Officer. "I'm thrilled to take on this ne

Kenvue Inc. (NYSE:KVUE) today announced its Board of Directors declared a quarterly dividend of $0.2075 per share on its common stock, which represents a 1.2 percent increase compared to the prior quarterly dividend. The quarterly dividend is payable on August 27, 2025, to shareholders of record as of the close of business on August 13, 2025. About Kenvue Kenvue Inc. is the world's largest pure-play consumer health company by revenue. Built on more than a century of heritage, our iconic brands, including Aveeno®, BAND-AID® Brand, Johnson's®, Listerine®, Neutrogena® and Tylenol®, are science-backed and recommended by healthcare professionals around the world. At Kenvue, we realize the ex

Kenvue Inc. (NYSE:KVUE) will announce its second quarter 2025 financial results before the market opens on August 7, 2025. The company will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss its financial results. The conference call can be accessed by dialing 877-407-8835 from the U.S. or +1 201-689-8779 from international locations. A live webcast of the conference call can also be accessed at investors.kenvue.com, with a replay made available after the live event. About Kenvue Kenvue Inc. is the world's largest pure-play consumer health company by revenue. Built on more than a century of heritage, our iconic brands, including Aveeno®, BAND-AID® Brand, Johnson's

Appoints Current Kenvue Director and Proven CPG and Technology Company Leader, Kirk Perry, as Interim CEO, Effective Immediately Announces Ongoing Review of Strategic Alternatives Reports Select Preliminary Second Quarter 2025 Financial Results Kenvue Inc. (NYSE:KVUE) today announced that its Board of Directors is implementing a set of actions to enable the Company to unlock shareholder value and reach its full potential. The Board has made a Chief Executive Officer transition and is advancing an ongoing comprehensive review of strategic alternatives. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250714520711/en/Kirk

Kenvue Inc. (NYSE:KVUE), maker of consumer health products like Tylenol®, Neutrogena® and Listerine®, today announced it has made the prestigious Fortune 500 list for the first time since becoming a fully independent company. With 2024 full year sales of $15.5 billion, Kenvue is listed at number 281. The company's debut is a testament to the power of its iconic brands and deep commitment to improving the health and well-being of consumers globally through science-backed, insights-led innovation. "Being named to the Fortune 500 list marks a significant milestone for Kenvue," said Thibaut Mongon, Chief Executive Officer. "Recognitions like this validate the hard work and dedication of our K

Combines Highly Complementary and Strategically Aligned Consumer Offerings, Including 10 Iconic Billion-Dollar Brands, That Will Provide Preferred Solutions Through Every Stage of Life Applies Kimberly-Clark's Proven Commercial Execution Playbook to Create a Best-in-Class Consumer-Driven Company Accelerates Kenvue's Premier Consumer Health Portfolio and Strong Science-Backed Innovation, Supported by Talented Kenvue Team Enhances Investment in Marketing, Innovation and R&D Capabilities to Strengthen Combined Company's Unique Advantages Total Anticipated Run-Rate Synergies of $2.1 Billion; Expected to Be Accretive to Kimberly-Clark's Adjusted EPS By Year 2 Delivers Immediate Upfront Value to K

Net Sales (3.5)%; Organic Sales1 (4.4)% Diluted EPS was $0.21; Adjusted Diluted EPS1 was $0.28 Affirms Outlook for FY'25 Kirk Perry Named Permanent Chief Executive Officer and Company Announced Additional Key Leadership Appointments Kenvue Inc. (NYSE:KVUE) today announced financial results for the third quarter ended September 28, 2025. "Throughout the third quarter, our team remained focused on our four operating priorities to drive improved performance," said Kirk Perry, Chief Executive Officer. "Third quarter results keep us on track to deliver our full year guidance and we are confident in the decisive actions we are taking to accelerate Kenvue's performance and unlock th

Kenvue Inc. (NYSE:KVUE) today announced that its Board of Directors declared a quarterly dividend of $0.2075 per share on its common stock. The quarterly dividend is payable on November 26, 2025, to shareholders of record as of the close of business on November 12, 2025. About Kenvue Kenvue Inc. is the world's largest pure-play consumer health company by revenue. Built on more than a century of heritage, our iconic brands, including Aveeno®, BAND-AID® Brand, Johnson's®, Listerine®, Neutrogena® and Tylenol®, are science-backed and recommended by healthcare professionals around the world. At Kenvue, we realize the extraordinary power of everyday care. Our teams work every day to put that po

Kenvue Inc. (NYSE:KVUE) will announce its third quarter 2025 financial results before the market opens on November 6, 2025. The company will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss its financial results. The conference call can be accessed by dialing 877-407-8835 from the U.S. or +1 201-689-8779 from international locations. A live webcast of the conference call can also be accessed at investors.kenvue.com, with a replay made available after the live event. About Kenvue Kenvue Inc. is the world's largest pure-play consumer health company by revenue. Built on more than a century of heritage, our iconic brands, including Aveeno®, BAND-AID® Brand, Johnson'

Net Sales (4.0)%; Organic Sales1 (4.2)% Diluted EPS was $0.22; Adjusted Diluted EPS1 was $0.29 Continues to Advance Ongoing Review of Strategic Alternatives, While Taking Actions to Accelerate Profitable Growth Under the New Executive Team Revises Outlook for FY'25 Kenvue Inc. (NYSE:KVUE) today announced financial results for the second quarter ended June 29, 2025. "Kenvue has a strong portfolio of world-class, category-defining brands. We are actively focused on improving execution and performance, while advancing the comprehensive strategic alternatives review, to deliver our inherent value," said Kirk Perry, Interim Chief Executive Officer. "I'm thrilled to take on this ne

Kenvue Inc. (NYSE:KVUE) today announced its Board of Directors declared a quarterly dividend of $0.2075 per share on its common stock, which represents a 1.2 percent increase compared to the prior quarterly dividend. The quarterly dividend is payable on August 27, 2025, to shareholders of record as of the close of business on August 13, 2025. About Kenvue Kenvue Inc. is the world's largest pure-play consumer health company by revenue. Built on more than a century of heritage, our iconic brands, including Aveeno®, BAND-AID® Brand, Johnson's®, Listerine®, Neutrogena® and Tylenol®, are science-backed and recommended by healthcare professionals around the world. At Kenvue, we realize the ex

Kenvue Inc. (NYSE:KVUE) will announce its second quarter 2025 financial results before the market opens on August 7, 2025. The company will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss its financial results. The conference call can be accessed by dialing 877-407-8835 from the U.S. or +1 201-689-8779 from international locations. A live webcast of the conference call can also be accessed at investors.kenvue.com, with a replay made available after the live event. About Kenvue Kenvue Inc. is the world's largest pure-play consumer health company by revenue. Built on more than a century of heritage, our iconic brands, including Aveeno®, BAND-AID® Brand, Johnson's

Net Sales (3.9)%; Organic Sales1 (1.2)% Maintains Focus On Accelerating Profitable Growth and Optimizing Cost Structure, While Successfully Completing TSA Exits Updates Outlook for FY'25 for Incremental Tariff Costs and Currency Kenvue Inc. (NYSE:KVUE) today announced financial results for the first quarter ended March 30, 2025. "In Q1, our teams executed our plans while continuing to navigate an evolving macro and consumer environment," said Thibaut Mongon, Chief Executive Officer. "We are committed and focused on activating our brands while staying agile and flexible to accelerate sustainable profitable growth." First Quarter Summary Net sales decreased 3.9% vs the prior year p

Kenvue Inc. (NYSE:KVUE) will announce its first quarter 2025 financial results before market open on May 8, 2025. The company will host a conference call and webcast at 8:00 a.m. Eastern Time to discuss its financial results. The conference call can be accessed by dialing 877-407-8835 from the U.S. or +1 201-689-8779 from international locations. A live webcast of the conference call can also be accessed at investors.kenvue.com, with a replay made available after the live event. About Kenvue Kenvue Inc. is the world's largest pure-play consumer health company by revenue. Built on more than a century of heritage, our iconic brands, including Aveeno®, BAND-AID® Brand, Johnson's®, Listerine

Kenvue Inc. (NYSE:KVUE) today announced that its Board of Directors has declared a quarterly dividend of $0.205 per share on its common stock. This quarterly dividend is payable on May 28, 2025, to shareholders of record as of the close of business on May 14, 2025. About Kenvue Kenvue Inc. is the world's largest pure-play consumer health company by revenue. Built on more than a century of heritage, our iconic brands, including Aveeno®, BAND-AID® Brand, Johnson's®, Listerine®, Neutrogena® and Tylenol®, are science-backed and recommended by healthcare professionals around the world. At Kenvue, we realize the extraordinary power of everyday care. Our teams work every day to put that power in

Appoints Current Kenvue Director and Proven CPG and Technology Company Leader, Kirk Perry, as Interim CEO, Effective Immediately Announces Ongoing Review of Strategic Alternatives Reports Select Preliminary Second Quarter 2025 Financial Results Kenvue Inc. (NYSE:KVUE) today announced that its Board of Directors is implementing a set of actions to enable the Company to unlock shareholder value and reach its full potential. The Board has made a Chief Executive Officer transition and is advancing an ongoing comprehensive review of strategic alternatives. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250714520711/en/Kirk

Kenvue Inc. (NYSE:KVUE), maker of consumer health products like Tylenol®, Neutrogena® and Listerine®, today announced it has made the prestigious Fortune 500 list for the first time since becoming a fully independent company. With 2024 full year sales of $15.5 billion, Kenvue is listed at number 281. The company's debut is a testament to the power of its iconic brands and deep commitment to improving the health and well-being of consumers globally through science-backed, insights-led innovation. "Being named to the Fortune 500 list marks a significant milestone for Kenvue," said Thibaut Mongon, Chief Executive Officer. "Recognitions like this validate the hard work and dedication of our K

Amit Banati, 30-Year Consumer Products Company Finance and Operations Veteran, Appointed CFO Succeeds Paul Ruh, Effective May 12, 2025 Kenvue Inc. (NYSE:KVUE), today announced the appointment of Amit Banati as the Company's Chief Financial Officer, effective May 12, 2025. He will be responsible for overseeing the Finance and Strategy functions, supporting initiatives aimed at accelerating profitable growth and delivering value to shareholders. Following a thorough and thoughtful search process, Mr. Banati will succeed Paul Ruh, who will remain with the Company for a brief period to help ensure a smooth transition. Mr. Banati is a 30-year consumer products company finance and operation

Company and Starboard Value LP Enter into Cooperation Agreement Kenvue Inc. (NYSE:KVUE), the world's largest pure-play consumer health company by revenue, today announced the appointment of two new independent directors, Sarah Hofstetter, President of Profitero, Ltd., and Erica Mann, former President and Head of Bayer's Consumer Health Division, to the Company's Board of Directors (the "Board"). Additionally, Jeffrey Smith, Managing Member, Chief Executive Officer and Chief Investment Officer of Starboard Value LP (together with certain of its affiliates, "Starboard") will join the Board. All three appointments are effective immediately. "We are pleased to welcome Sarah, Erica and Jeff as

Kathleen Pawlus, Retired Partner and Global Assurance Chief Financial Officer and Chief Operating Officer at EY, and Kirk Perry, Circana President and CEO and Former Procter & Gamble and Google Executive, to Join the Board of Directors Current Johnson & Johnson Executives to Step Down from Kenvue Board of Directors Kenvue Inc. ("Kenvue" or the "Company") (NYSE:KVUE), the world's largest pure-play consumer health company by revenue, today announced the implementation of a Board of Directors ("the Board") succession process, in line with the Company's commitment to best-in-class corporate governance and independent Board oversight. Appointment of Two New Independent Directors to the Boa